Healthcare
Live Price
Offline$0.4949
+0.00% today
1Y Change
-19.84%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tong Ren Tang Technologies Co. Ltd. (TGRNF) is a Healthcare stock with a market cap of $4.38B and listed on OTC. The stock last traded around $0.49 and down 19.8% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -13.0%, EPS growth of -26.8%, a dividend yield of 5.0%. What stands out right now is revenue -13.0%, EPS -26.8%, free cash flow +1011.7% with operating margin 12.5% and ROIC 5.2%. The dividend matters to the case here, with a current yield around 5.0%. Valuation is more restrained than many high-expectation growth names at P/E 11.1 and price/sales 0.7. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines TGRNF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TGRNF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TGRNF Max Drawdown
-29.30%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TGRNF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$5.4B
-9.9% YoY
FY Net Income
$507.2M
-13.0% YoY
Free Cash Flow
-$110.1M
-112.6% YoY
Revenue Growth
-13.0%
EPS Growth
-26.8%
Gross Margin
38.0%
Net Margin
6.1%
Income statement
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 6.3B | 7.3B | 6.8B | 6.0B | 5.4B |
| Gross Profit | 2.4B | 2.9B | 2.8B | 2.6B | 2.3B |
| Operating Income | 785M | 985M | 1.1B | 1.2B | 1.1B |
| EBITDA | 785M | 1.4B | 1.3B | 1.4B | 1.3B |
| Net Income | 386M | 522M | 590M | 583M | 507M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.7B | 4.1B | 2.7B | 3.7B | 3.2B |
| Total Assets | 13.7B | 14.4B | 13.5B | 12.5B | 11.6B |
| Total Liabilities | 3.3B | 4.2B | 3.9B | 3.5B | 3.4B |
| Shareholder Equity | 7.3B | 7.2B | 6.9B | 6.5B | 6.0B |
| Total Debt | 715M | 2.4B | 1.6B | 1.6B | 1.6B |
| Net Debt | -4.0B | -1.7B | -1.1B | -2.1B | -1.6B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
436M
-57.8% YoY
Capital Expenditures
546M
-249.0% YoY
Free Cash Flow
110M
-112.6% YoY
Key ratios
Gross Margin
38.0%
Operating Margin
12.5%
Net Margin
6.1%
ROE
5.4%
Debt / Equity
0.30x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.